4693-01-0

Usage

Uses

Used in Organic Synthesis:
1-methyl-6-nitro-2H-3,1-benzoxazine-2,4(1H)-dione is used as a key intermediate in the synthesis of various organic compounds for different applications, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure and reactivity make it a valuable component in the creation of complex molecules.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-methyl-6-nitro-2H-3,1-benzoxazine-2,4(1H)-dione is used as a building block for drug development. Its structural features and chemical properties allow it to be a precursor in the synthesis of new drug candidates, potentially leading to the discovery of novel therapeutic agents.
Used in Research and Development:
1-methyl-6-nitro-2H-3,1-benzoxazine-2,4(1H)-dione is also utilized in research and development settings to explore its chemical properties and potential applications. Scientists and researchers use 1-methyl-6-nitro-2H-3,1-benzoxazine-2,4(1H)-dione to study its reactivity, stability, and interactions with other molecules, which can contribute to the advancement of chemical knowledge and the development of new technologies.

InChI:InChI=1/C9H6N2O5/c1-10-7-3-2-5(11(14)15)4-6(7)8(12)16-9(10)13/h2-4H,1H3

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 77-78-1 dimethyl sulfate 
• 616-79-5 2-amino-5-nitro-benzoic acid 
• 4693-02-1 6-nitroisatoic anhydride 
• 74-88-4 methyl iodide 

Downstream Products

• 77423-11-1 2-Methylamino-5-nitro-benzoic acid hydrazide 
• 1268263-73-5 spiro{(1',4'-anhydro-2',3',5'-tri-O-benzyl-L-arabinitol)-1',2-[(11aS)-7-nitro-10-methylpyrrolo[2,1-c][1,4]benzodiazepine-5,11-dione]} 
• 1356111-73-3 tert-butyl 5-amino-2-(methylamino)benzoate 
• 1609243-43-7 tert-butyl 5-(3-{[2-(1-{5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl]pentanamido}-3,6,9,12-tetraoxapentadecan-15-amido)ethyl]disulfanyl}propanamido)-2-(methylamino)benzoate 
• 1609243-42-6 tert-butyl 2-(methylamino)-5-nitrobenzoate 
• 1032571-34-8 spiro{(1',4'-anhydro-2',3',5'-tri-O-benzyl-D-arabinitol)-1',2-[(11aR)-7-nitro-10-methylpyrrolo[2,1-c][1,4]benzodiazepine-5,11-dione]} 
• 77422-99-2 PD 90780 
• 77422-98-1 7-(acetylamino)-4,9-dihydro-4-methyl-9-oxopyrazolo<5,1-b>quinazoline-2-carboxylic acid 
• 77423-09-7 5-amino-2-methylaminobenzoic acid hydrazide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of E-ring modified evodiamine derivatives as novel antitumor agents

A series of novel E-ring modified evodiamine derivatives were designed and synthesized as antitumor agents. Their capacity to interfere with the catalytic activity of topoisomerase I and II was evaluated by the relaxation assay. In vitro antitumor activity results revealed that compound 12 showed good antitumor activity with a broad spectrum. Its binding modes with topoisomerase I and II were clarified by molecular docking.

[1,4]OXAZEPINO[2,3-C]QUI NOLI NONE DERIVATIVES AS BLC6 INHIBITORS

The present invention relates to compounds that function as inhibitors of BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket

We describe the optimization of modestly active starting points to potent inhibitors of BCL6 by growing into a subpocket, which was occupied by a network of five stably bound water molecules. Identifying potent inhibitors required not only forming new interactions in the subpocket but also perturbing the water network in a productive, potency-increasing fashion while controlling the physicochemical properties. We achieved this goal in a sequential manner by systematically probing the pocket and the water network, ultimately achieving a 100-fold improvement of activity. The most potent compounds displaced three of the five initial water molecules and formed hydrogen bonds with the remaining two. Compound 25 showed a promising profile for a lead compound with submicromolar inhibition of BCL6 in cells and satisfactory pharmacokinetic (PK) properties. Our work highlights the importance of finding productive ways to perturb existing water networks when growing into solvent-filled protein pockets.

BCL6 INHIBITORS

The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity Formula (I) wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

Biotin-conjugated N-methylisatoic anhydride: A chemical tool for nucleic acid separation by selective 2′-hydroxyl acylation of RNA

An isatoic anhydride derivative conjugated to a biotin and a disulfide linker was specifically designed for the separation of nucleic acids. Starting from a DNA-RNA mixture, a selective 2′-hydroxyl acylation of RNAs followed by capture with streptavidin-coated magnetic beads and cleavage of the disulfide led to elution of RNAs. the Partner Organisations 2014.